Development of a mass spectrometry-enabled assay for the identification of new cellular targets for antibody-drug conjugates that utilize a novel payload delivery mechanism

ImmunoBiochem已经开发出一种颠覆性的技术，将彻底改变抗体-药物偶联（ADC）治疗领域。adc是一种新型的靶向治疗药物，它结合了单克隆抗体的高特异性和高效的小分子化疗药物，能够选择性地、有效地向癌细胞输送有毒物质。免疫生物化学公司的下一代肿瘤adc采用了一种新的方法，能够基于细胞内肿瘤抗原或癌症生物标志物靶向实体肿瘤，这些抗原或生物标志物被认为是不可药物的，靶向生物疗法无法获得。免疫生物化学先导adc， IMB-101和IMB-102，是针对一种未公开的细胞内肿瘤抗原，是一种临床验证的癌症生物标志物，与传统的受体靶向adc相比，对癌细胞具有更高的选择性。因此，IMB-101和IMB-102提供了优越的安全性和广泛的治疗窗口，防止了许多ADC（包括临床批准的ADC，曲妥珠单抗DM1 （Kadcyla®））常见的针对正常健康细胞的靶向毒性。IMB-101和IMB-102正在开发用于三阴性乳腺癌（TNBC），这是一种侵袭性疾病，目前尚无靶向生物治疗方案。拟议的工作将使ImmunoBiochem能够利用质谱和定量肿瘤蛋白质组学方面的学术专业知识，开发和验证一种检测方法，用于发现ADC治疗的新细胞靶点，这些靶点可以利用ImmunoBiochem新的有效载荷传递机制。

ImmunoBiochem has developed a disruptive technology that will revolutionize the field of Antibody-Drug Conjugate (ADC) therapeutics. ADCs comprise a novel class of targeted therapeutics that combine the high specificity of monoclonal antibodies with highly-potent chemotherapeutic small-molecule drugs, and are able to selectively and efficaciously deliver a toxic payload to cancer cells. ImmunoBiochems next-generation ADCs for oncology utilize a novel approach that enables the targeting of solid tumors based on intracellular tumor antigens or cancer biomarkers that are considered undruggable and inaccessible to targeted biological therapeutics. ImmunoBiochems lead ADCs, IMB-101 and IMB-102, are targeted at an undisclosed intracellular tumor antigen that is a clinically-validated cancer biomarker, and offer superior selectivity for cancer cells compared to conventional receptor-targeted ADCs. IMB-101 and IMB-102 thus offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs, including the clinically approved ADC, trastuzumab DM1 (Kadcyla®). IMB-101 and IMB-102 are being developed for Triple-Negative Breast Cancer (TNBC), an aggressive disease for which no targeted biological therapeutic treatment options are currently available. The proposed work will enable ImmunoBiochem to leverage academic expertise in mass spectrometry and quantitative onco-proteomics to develop and validate an assay for the discovery of new cellular targets for ADC therapeutics that can take advantage of ImmunoBiochems new payload delivery mechanism.